Clinical case of severe bronchial asthma in an adolescent

Bronchial asthma is one of the most common diseases in children (in the Russian Federation, the prevalence among children and adolescents is about 10 %). In modern management of severe bronchial asthma, a thorough analysis of risk factors that determine the progression of the disease and the formation of a severe course is important, which allows for a personalized approach to prevention and treatment. The article presents a clinical case of an adolescent with severe uncontrolled bronchial asthma, who, despite multiple corrections of basic therapy, continued to have frequent exacerbations and a severe course of the disease. The experience of using biological therapy is shown and the adverse effects associated with it are described. Clinical methods, dynamic assessment of laboratory and instrumental parameters, comparison of the clinical and laboratory course of the disease in dynamics are used. The patient's examination data and an assessment of the effectiveness of mepolizumab and dupilumab in the context of improving the control of bronchial asthma symptoms in this adolescent are presented. A clinical case of a 15-year-old girl shows that uncontrolled severe bronchial asthma with concomitant eosinophilia can be successfully corrected using biological therapy. The data obtained emphasize the importance of differential diagnosis and an individual approach to the choice of biological therapy in patients with severe bronchial asthma, especially in cases of ineffectiveness of standard treatment approaches. 

1. Ministry of Health of the Russian Federation. Bronchial asthma: clinical guidelines. Moscow; 2024: 15–16.

2. Baranovskaya T. V., Belevsky A. S., Voskanyan A. G., Gadzhiev K. M., Davletalieva N. E., Emelianov A. V., Kurbacheva O. M., Knyazheskaya N. P., Mukatova I. Yu., Nenasheva N. M. Severe bronchial asthma – 2018. Consensus report of the joint expert group of the Association of Russian-speaking specialists in the field of respiratory medicine. 2018. 25 p.

3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2024. Available at: https://ginasthma.org (accessed: 01.05.2025).

4. Kumar V., Sharma A., Bansal P., Gupta A., Ranjan P., Singh A. Tropical Pulmonary Eosinophilia: A Review. URL: https://jpp.mums.ac.ir/article_6603_3fc2cbc22ad952a17981a034fe070f15.pdf.

5. Jaffe E. S., Harris N. L., Stein H., Pileri S. A., Swerdlow S. H., Campo E., Krenacs L., Müller-Hermelink H. K., Friedberg J. W., Nakamura S., Kawamoto H., Pang J. C. N., Meyer P. R., Floyd J. A., Vardiman J. W. The World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumors. 2016.

6. Lie J. T., Arend W. P., Bloch D. A., Hunder G. G., Lightfoot R. W., Masi A. T., McAdam L. P., Michel B. A., O'Duffy J. D., and the American College of Rheumatology Subcommittee on Classification of Vasculitis. Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum. 1990; 33 (8): 1074–1087. doi: 10.1002/art.1780330804.

7. Churg A., G. A. W. Recent advances in the diagnosis of Churg–Strauss syndrome. Modern Pathology. 2001; 14 (12): 1284–1293. doi: 10.1038/modpathol.3880475.

8. Katzenstein A. L., Myers J. L. Diagnostic features and differential diagnosis of Churg – Strauss syndrome in the lung: a review. American Journal of Clinical Pathology. 2000; 114 (5): 767–772. doi: 10.1309/F3FW-J8EB-X913G1RJ.

9. Shinkai A., Yoshisue H., Koike M., Matsumoto K., Hasegawa Y., Takahashi M., Takeda K., Matsushima K. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. Journal of Immunology. 1999; 163 (3): 1602–1610.

10. Demko I. V., Sobko E. A., Chubarova S. V., Levin A. Yu., Kiselev A. A. Features of systemic inflammation, respiratory function, and morphological structure of the bronchial mucosa in severe bronchial asthma. Siberian Medical Review. 2014; 10: 47–52.

11. Ortega H. G., Liu M. C., Pavord I. D., Brusselle G. G., FitzGerald J. M., O'Byrne P. M., and the MENSA Study Group. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma: The MENSA Study. The New England Journal of Medicine. 2014; 371 (13): 1198–1207. doi: 10.1056/NEJMoa1403293.

12. Pavord I. D., Korn S., Fleming L. J., Verbeek P. R., and the DREAM Study Group. Mepolizumab for the Treatment of Severe Eosinophilic Asthma: The DREAM Study. The New England Journal of Medicine. 2012; 367 (2): 159–169. doi: 10.1056/NEJMoa1103013.